ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Beta Bionics Introduces Bionic Insights™ in Bionic Reports — Transforming How Clinicians Understand and Optimize Diabetes Care

IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Beta Bionics today announced the launch of Bionic Insights™, an innovative new feature within its Bionic Reports, designed to help healthcare providers (HCPs) make more informed, personalized treatment recommendations for people living with diabetes.

As the first and only insulin pump company to deliver this level of intelligent reporting, Beta Bionics is redefining how clinicians interpret patient data. Bionic Insights goes beyond traditional glucose reporting by surfacing clinically relevant indicators, patient activities and system events that directly influence outcomes – giving providers unprecedented clarity into what’s working and where support is needed.

“Bionic Insights can change how clinicians interact with diabetes data,” said Steven Russell, MD, PhD, Chief Medical Officer at Beta Bionics, “because it transforms complex data into clear, actionable guidance. It highlights successes and opportunities, allowing physicians to have more productive conversations with their patients and make targeted recommendations that improve outcomes. This is an important step forward in helping people achieve better glucose control.”

Turning Data into Actionable Insight
Bionic Insights introduces a new level of intelligence within the Bionic Report by organizing information into two key categories:

  • Areas of Success – such as strong time in range, stable overnight glucose, and mostly usual meal announcements – enabling providers to reinforce positive interactions.
  • Areas of Opportunity – including frequent insulin pauses, rebound highs, prolonged hyperglycemia, or missed meal announcements – paired with educational guidance to support improvement.

This structured approach allows clinicians to quickly identify the drivers behind glucose outcomes, reducing time spent interpreting raw data and increasing time spent on meaningful patient care decisions.

“Bionic Insights gives both providers and patients a shared understanding of what’s happening and why,” added Dr. Russell. “That clarity makes it easier to have focused, productive conversations with patients about how to get the most from their iLet.”

With Bionic Insights, Beta Bionics continues its mission to simplify diabetes management and improve lives through innovation – bringing smarter, more intuitive tools to the forefront of automated insulin delivery.

About Beta Bionics
Headquartered in Irvine, California, Beta Bionics, Inc. is redefining what’s possible in diabetes care. By listening to people living with diabetes, their families, and their care teams, the company created the iLet Bionic Pancreas – the only automated insulin delivery system with a closed loop algorithm that adapts to each person in order to determine and deliver every insulin dose, reducing the daily burden on users. With this unique, innovative approach, Beta Bionics is focused on bringing greater ease, confidence, and freedom to people managing diabetes every day. To learn more, visit www.betabionics.com.

Investor Relations Contact:
ir@betabionics.com

Media and Public Relations Contact:
media@betabionics.com


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  238.38
+0.00 (0.00%)
AAPL  260.48
+0.00 (0.00%)
AMD  245.04
+0.00 (0.00%)
BAC  52.54
+0.00 (0.00%)
GOOG  315.72
+0.00 (0.00%)
META  629.86
+0.00 (0.00%)
MSFT  370.87
+0.00 (0.00%)
NVDA  188.63
+0.00 (0.00%)
ORCL  138.09
+0.00 (0.00%)
TSLA  348.95
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.